Moderna Inc Corporate Analyst Meeting Transcript
© -
Good morning. Welcome to Moderna's third annual R&D meeting. Thank you for joining us in person in the room. And for those of you joining us via webcast, thanks for joining in. We're very pleased to host you today and to share some interesting new data about Moderna's platform that are important for patients.
Before we start, let me remind you, we'll be making forward-looking statements that make mRNA to be a risky endeavor. And I invite you to check our risk factors on the SEC website or on the Moderna website.
As many of you know, since we started the company, we thought that mRNA could be a very powerful new potential class of medicine. What excited us is the possibility of doing not only secreted protein but also intracellular and transmembrane. And when you think that the majority of a protein encoded in the human genome are coded for transmembrane and intracellular protein, there could be a very large possibility to help patients.
We believe because mRNA is an information molecule that we'll have a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |